Aquestive Therapeutics Inc (AQST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
Cash Flows From Operating Activities | |||||
Net Income | -44,137 | -7,870 | -54,410 | -70,539 | -55,783 |
Depreciation Amortization | 11,432 | 3,317 | 2,602 | 6,695 | 6,030 |
Accounts receivable | 1,094 | -3,073 | 7,352 | -5,353 | 6,175 |
Other Working Capital | -9,957 | -5,341 | 31,977 | -1,730 | -4,413 |
Other Operating Activity | 5,809 | 6,587 | 2,660 | 37,948 | 2,532 |
Operating Cash Flow | $-35,759 | $-6,380 | $-9,819 | $-32,979 | $-45,459 |
Cash Flows From Investing Activities | |||||
PPE Investments | -159 | -995 | -1,024 | -913 | -517 |
Purchase Sale Intangibles | N/A | N/A | -1,500 | 0 | N/A |
Other Investing Activity | 0 | 0 | -1,500 | 0 | 0 |
Investing Cash Flow | $-159 | $-995 | $-2,524 | $-913 | $-517 |
Cash Flows From Financing Activities | |||||
Debt Issued | N/A | 31,144 | N/A | N/A | N/A |
Debt Repayment | -23 | -53,631 | -2,025 | 0 | -24,750 |
Common Stock Issued | 84,721 | 17,259 | 13,620 | 30,123 | 6,215 |
Other Financing Activity | -1,106 | 9,202 | -3 | -14 | 46,992 |
Financing Cash Flow | $83,592 | $3,974 | $11,592 | $30,109 | $28,457 |
Beginning Cash Position | 23,872 | 27,273 | 28,024 | 31,807 | 49,326 |
End Cash Position | 71,546 | 23,872 | 27,273 | 28,024 | 31,807 |
Net Cash Flow | $47,674 | $-3,401 | $-751 | $-3,783 | $-17,519 |
Free Cash Flow | |||||
Operating Cash Flow | -35,759 | -6,380 | -9,819 | -32,979 | -45,459 |
Capital Expenditure | -159 | -995 | -1,024 | -913 | -517 |
Free Cash Flow | -35,918 | -7,375 | -10,843 | -33,892 | -45,976 |